We are living in a new era of medicine, where treatments and even cures once believed to be impossible are today a reality. But this immense progress does not apply universally and there have been far more setbacks in Alzheimer's research than success. For example, between 1998 and 2017, there were 146 attempts to bring new Alzheimer’s treatments to market, but just four successful approvals. Even then, medicines approved today only treat symptoms and not the underlying cause of the disease.
On September 12, in partnership with The Atlantic, researchers, patient advocates and policymakers who help advance drug discovery, will gather in Chicago to discuss the unique challenges which make up Alzheimer's research and what the future holds for the 5.7 million Americans living with the disease. Featured as part of the event will be Peter Anastasiou, president of Lundbeck North America. Peter will be joined on stage by Samantha Budd Haeberlein, vice president, Alzheimer’s Late Stage Clinical Development, Biogen and Johan Luthman, vice president and Head of Clinical Development, Global Neurology Business Group, Eisai.
A week later, on September 17, a similar group will gather in Washington, D.C. to view acclaimed filmmaker and director James Keach’s The Turning Point, which follows a team of dedicated biopharmaceutical scientists on the front lines of Alzheimer’s research and captures the raw disappointment and renewed hope of those working to find a cure.
At both events, audience members will explore the uphill battle to fight the loss of the cognitive functions of the brain. Of the top 10 causes of death, Alzheimer's is the only one that cannot be prevented, cured or even slowed. Once diagnosed, the average life expectancy is seven years, during which patients go through the horrifying experience of losing their memories.
Despite setbacks in the field, progress has been made. Many researchers point out that a “failed experiment” is not the same thing as a “failure” because even when a medicine does not make it through the clinical trial process, biopharmaceutical researchers are still able to glean useful information that advance our understanding of the brain. And today there are 92 medicines in development for the treatment of Alzheimer’s disease.
This year, the results of an early trial for an experimental drug demonstrated the ability to improve cognition and reduce clinical signs of Alzheimer's in study participants. While these results far from indicate a successful treatment, they reflect progress nonetheless.
These stepping stones in research will ultimately escalate into a giant leap forward, providing hope to the millions of Alzheimer’s patients and their caregivers and loved ones.
Andrew Powaleny
Andrew Powaleny is the Deputy Vice President of Public Affairs at PhRMA, where he leads communications on scientific, regulatory and intellectual property issues, highlighting the biopharmaceutical industry’s efforts in developing innovative medicines and vaccines while promoting an environment that encourages necessary risk-taking. For five years starting in 2019, he launched and led PhRMA’s grassroots initiative, Voters for Cures, bringing patients and caregivers together to advocate for access to medicine and biopharmaceutical innovation. He also co-founded and co-chaired PRIDE Umbrella, a resource group for LGBTQ+ individuals. Prior to joining PhRMA in 2015, Andrew worked as a communications consultant in Washington, D.C., and as Deputy Press Secretary for the U.S. House Committee on Energy and Commerce under Chairman Fred Upton. He holds a degree in public policy and government from Eastern Connecticut State University, with a minor in music. Outside of work, Andrew enjoys exercise, musical theater and mentoring college students through The Fund for American Studies alumni association.
Andrew Powaleny
Alzheimer's & Brain Awareness Month: A conversation with Biogen
Alzheimer's & Brain Awareness Month: A conversation with Eisai
Alzheimer's & Brain Awareness Month: A conversation with Eli Lilly and Company
What new cures would mean to families
CMS coverage policy is detrimental to Alzheimer’s patients
CMS coverage policies restrict patient access to important treatment options for Alzheimer’s disease
CMS coverage decision restricts access to treatments for Alzheimer’s disease
PhRMA submits comments urging CMS to withdraw coverage proposal
ICYMI: New approvals by the FDA in 2021 offer greater treatment options for patients
New report shows more than 260 medicines in development to fight neurodegenerative diseases
How research evolves and brings new hope to patients
Continued R&D into Alzheimer’s disease means hope for patients, families and caregivers
2020 FDA approvals show innovation despite COVID-19 pandemic challenges
Report: More than 1,300 medicines and vaccines in development to help fight cancer
Guest Post: Honoring Hispanic Heritage Month by taking action on health equity
New report shows more than 400 medicines and vaccines in development to tackle infectious diseases, including COVID-19
New report explores setbacks that bring future cancer success stories
What scientific experts are saying about vaccine safety
New report shows nearly 260 vaccines in development, including dozens for COVID-19
ICYMI: 2019 brings innovative medicines to patients
PhRMA comments to Congress on Cures 2.0 call to action
Speaker Pelosi’s drug pricing plan could result in 56 fewer new medicines over 10 years
Nearly 140 medicines in development to treat mental illness
New report finds 15 new oncology therapies launched last year
Clinical Trials Awareness Week: Celebrating innovation in clinical research
Event: New era of medicine comes to Capitol Hill
New report shows more than 160 medicines in development for diabetes and related conditions
Minority health matters
New report shows nearly 20 innovative medicines in development for sickle cell disease
130 medicines in development for asthma, allergies and other respiratory diseases
130 medicines in development for asthma, allergies and other respiratory diseases
Putting 2018 medicine approvals in context
New report details the setbacks and challenges to Alzheimer’s research
Aspen Spotlight Health: Discussing the forefront of innovation
Nearly 60 biopharmaceutical researchers GoBoldly on Capitol Hill
New report and resources put cancer in context, showing more than 1,100 medicines and vaccines in development
Video: PhRMA CEO discusses biopharmaceutical supply chain at POLITICO event
A new era in Alzheimer’s innovation
New report shows over 500 medicines in development for neurological disorders
Rare Disease Day: Unmet need inspires innovation
ICYMI: Why 2017 medicine approvals matter
ICYMI: Report highlights increasing prevalence for Alzheimer’s disease
New report and event examine the new era of vaccines
A new era in cancer
Profiles in courage: Latinos in the fight against Alzheimer’s
How biopharmaceutical collaboration is driving a new era of medicine
Putting the bio in biotech: How Bay Area minds are powering biopharmaceutical innovation
Finding cures for incurable diseases
New report portrays flourishing pipeline
Going boldly together: New advancements and new anniversaries
Examining the brain in The New Era of Medicine
A New World of Medicine: New GOBOLDLY ads showcase groundbreaking scientific advancements
Medicare Monday: How finding an Alzheimer’s treatment could lower Medicare spending
ICYMI: The New Era of Medicine initiative spotlights genomics in NYC
A new era in genomics
ICYMI: New era of medicine initiative kicks off in Boston
Exploring the new era of medicine
Guest Post: Johnson and Johnson is celebrating outstanding scientists: Who will be next?
This is not a video game: New TV ad showcases the destruction of a cancer cell by immune system
VIDEO: PhRMA CEO discusses #GOBOLDLY campaign and White House meeting with CNNMoney’s Maggie Lake
VIDEO: PhRMA CEO joins CNBC’s Squawk on the Street to discuss industry campaign #GOBOLDLY
The 20-year journey yielding a new weapon against cancer
Disrupting Alzheimer's
Alzheimers
New Era of Medicine
Disrupting Alzheimer's
Disrupting Alzheimer's